Clinical Trial Update: Tirzepatide in MetALD [Phase 2]

View source ↗

Summary

A Phase 2 clinical study is evaluating tirzepatide for Metabolic Alcohol-associated Liver Disease and Alcohol Use Disorder; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder
• Metabolic Alcohol-associated Liver Disease

Drugs mentioned

• Tirzepatide (Mounjaro) (tirzepatide)

Snippet

Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Conditions: Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder | Phase 2 | Status: RECRUITING